

PCT

AstraZeneca



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Davies et al	Filing Date: Not yet assigned
Application No.: 10/524986	Attorney Docket No.: 100813 -1P US
PCT Application No.: PCT/GB03/03606	Examiner: Not yet assigned
Title: INDOLYLALKYLAMINO-METHYLIDENECARBAMATE DERIVATIVES USEFUL AS GNRH ANTAGONISTS	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 19, 2005

Signature

Bernadette Holder

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

AstraZeneca R&D Boston
A business unit of AstraZeneca Pharmaceuticals LP
35 Gatehouse Drive
Waltham MA 02451
USA

Tel +1 781-839-4000
Fax +1 781-839-4500


REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:
before the mailing of the **first Office Action** on the merits, and therefore no fee is believe due.

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100746-1P US.

Respectfully submitted,



Name: Christine McCormack
Dated: August 19, 2005
Reg. No.: L0065
Phone No.: 781-839-4693

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 01760

Enclosures: Form SB08A (3 sheets – 30 documents)
Form SB08B (2 sheets – 15 documents)
IPER
Search Report
Return Receipt Postcard

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 1 of 5

Complete if Known

Application Number 10/524986
Filing Date Not yet assigned
First Named Inventor DAVIES, Robert
Art Unit Not yet assigned
Examiner Name Not yet assigned
Attorney Docket No. 100813-1P US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†*
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/GS/	AA	WO 97/21435 A1	06-19-1997			<input type="checkbox"/>
	AB	WO 97/21703 A1	06-19-1997			<input type="checkbox"/>
	AC	WO 99/20599 A1	04-29-1999			<input type="checkbox"/>
	AD	WO 02/92565 A2	11-21-2002			<input type="checkbox"/>
	AE	WO 02/66459 A1	08-29-2002			<input type="checkbox"/>
	AF	WO 00/69433 A1	11-23-2000			<input type="checkbox"/>
	AG	WO 00/04013 A1	01-27-2000			<input type="checkbox"/>
	AH	WO 99/41252 A1	08-19-1999			<input type="checkbox"/>
	AI	WO 99/41251 A1	08-19-1999			<input type="checkbox"/>
	AJ	WO 99/21557 A1	05-06-1999			<input type="checkbox"/>
	AK	WO 99/21553 A1	05-06-1999			<input type="checkbox"/>
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 2 of 5

Complete if Known

Application Number 10/524986
Filing Date Not yet assigned
First Named Inventor DAVIES, Robert
Art Unit Not yet assigned
Examiner Name Not yet assigned
Attorney Docket No. 100813-1P US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ⁵ - Kind Code ⁶ (if known)				
/GS/	AL	WO 98/55479 A1	12-10-1998			<input type="checkbox"/>
	AM	WO 98/55470 A1	12-10-1998			<input type="checkbox"/>
	AN	WO 98/55123 A1	12-10-1998			<input type="checkbox"/>
	AO	WO 98/55119 A1	12-10-1998			<input type="checkbox"/>
	AP	WO 98/55116 A1	12-10-1998			<input type="checkbox"/>
	AQ	WO 97/21707 A1	06-19-1997			<input type="checkbox"/>
	AR	WO 97/21704 A1	06-19-1997			<input type="checkbox"/>
	AS	WO 00/53602 A1	08-14-2000			<input type="checkbox"/>
	AT	WO 00/53185 A1	08-14-2000			<input type="checkbox"/>
	AU	WO 00/53181 A1	08-14-2000			<input type="checkbox"/>
	AV	WO 00/53180 A1	08-14-2000			<input type="checkbox"/>
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 3 of 5


Complete if Known

Application Number	10/524986
Filing Date	Not yet assigned
First Named Inventor	DAVIES, Robert
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100813-1P US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁵ (if known)					
/GS/ 	AW	WO 00/53179 A1		08-14-2000			<input type="checkbox"/>
	AX	WO 00/53178 A1		08-14-2000			<input type="checkbox"/>
	AY	WO 99/51596 A1		10-14-1999			<input type="checkbox"/>
	AZ	WO 99/51595 A1		10-14-1999			<input type="checkbox"/>
	BA	WO 99/51234 A1		10-14-1999			<input type="checkbox"/>
	BB	WO 99/51233 A1		10-14-1999			<input type="checkbox"/>
	BC	WO 99/51232 A1		10-14-1999			<input type="checkbox"/>
	BD	WO 99/51231 A1		10-14-1999			<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
Examiner Signature					Date Considered		

***EXAMINER.** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and) (by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 4 of 5

Complete if Known

Application Number	10/524988
Filing Date	Not yet assigned
First Named Inventor	DAVIES, Robert
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100813-1P US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/GS/	BE	ASHTON et al 'Substituted Indole-5-carboxamides and -acetamides as Potent Nonpeptide GnRH Receptor Antagonist.' Bioorganic & Medicinal Chemistry Letters 2001, vol. 11, pp. 1723-1726.	<input type="checkbox"/>
	BF	ASHTON et al 'Potent Nonpeptide GnHR Receptor Antagonists Derived from Substituted Indole-5-carboxamides and -acetamides Bearing a Pyridine Side-Chain Terminus.' Bioorganic & Medicinal Chemistry Letters 2001, vol. 11, pp. 1727-1731.	<input type="checkbox"/>
	BG	ASHTON et al 'Orally Bioavailable, Indole-Based Nonpeptide GnHR Receptor Antagonists with High Potency and Functional Activity.' Bioorganic and medicinal Chemistry Letters 2001, vol. 11, pp. 2597 - 2602.	<input type="checkbox"/>
	BH	CHU et al. 'Initial Structure-Activity Relationship of a Novel Class of Nonpeptidyl GnHR Receptor Antagonists: 2-Arylindoles.' Bioorganic and Medicinal Chemistry Letters 2001, vol. 11, pp. 509 - 513.	<input type="checkbox"/>
	BI	CHU et al. 'SAR Studies of novel 5-Substituted 2-Arylindoles as Nonpeptidyl GnHR Receptor Antagonists.' Bioorganic and Medicinal Chemistry Letters 2001, vol. 11, pp. 515 - 517.	<input type="checkbox"/>
	BJ	FREIDINGER, R. M. 'Nonpeptide ligands for peptide and protein receptors.' Current Opinion in Chemical Biology 1999, vol. 3, pp. 395 - 406.	<input type="checkbox"/>
	BK	GOULET, M. T. 'Gonadotropin Releasing Hormone Antagonists.' Annual Reports in Medicinal Chemistry 1995, vol. 30, pp. 169 - 178.	<input type="checkbox"/>
	BL	LIN et al. '2-(3,5-Dimethylphenyl)tryptamine Derivatives That Bind to the GnHR Receptor.' Bioorganic & Medicinal Chemistry Letters 2001, vol. 11, pp. 1073 - 1076.	<input type="checkbox"/>
	BM	LIN et al. 'Heterocyclic Derivatives of 2-(3,5-Dimethylphenyl)tryptamine as GnHR Receptor Antagonists.' Bioorganic & Medicinal Chemistry Letters 2001, vol. 11, pp. 1077 - 1080.	<input type="checkbox"/>
	BN	SIMOENE, J. P. 'Synthesis of chiral β -methyl tryptamine-derived GnHR antagonists.' Tetrahedron Letters 2001, vol. 42, pp. 6459 - 6461.	<input type="checkbox"/>
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET 5 of 5

Complete if Known

Application Number	10/524988
Filing Date	Not yet assigned
First Named Inventor	DAVIES, Robert
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100813-1P US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	† ²
/GS/	BO	WALSH et al. 'A convergent synthesis of (S)- β -methyl-2-aryltryptamine based gonadotropin releasing hormone antagonists.' Tetrahedron, 2001, vol. 57, pp. 5233 - 5241.	<input type="checkbox"/>
	BP	YOUNG et al. '2-Arylindoles as Gonadotropin Releasing Hormone (GnHR) Antagonists: Optimization of the Tryptamine Side Chain.' Bioorganic & Medicinal Chemistry Letters, 2002, vol. 12, pp. 827 - 832.	<input type="checkbox"/>
	BQ	UJJAINWALLA, F. 'Total synthesis of 6- and 7-azaindole derived GnHR antagonists.' Tetrahedron Letters, 2001, vol. 42, pp. 6441 - 6445.	<input type="checkbox"/>
	BR	SIMEONE, J. P et al. 'Modification of the Pyridine Moiety of Non-peptidyl Indole GnHR Receptor Antagonists.' Bioorganic & Medicinal Chemistry Letters, 2002, vol. 12, pp. 3329 - 3332.	<input type="checkbox"/>
	BS	GIBBS, J. B. 'Pharmaceutical Research in Molecular Oncology.' Cell, 1994, vol. 79, pp. 193 - 198.	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
Examiner Signature	/Golam Shameem/		Date Considered 02/11/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.²This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /GS/